Sino Biopharmaceutical Limited

SEHK:1177 Stok Raporu

Piyasa değeri: HK$59.2b

Sino Biopharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Sino Biopharmaceutical şirketinin kazançları yıllık ortalama -13.6% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 5.7% oranında artan oldu. Gelirler yıllık ortalama 2.9% oranında artan oldu. Sino Biopharmaceutical şirketinin öz sermaye getirisi 12% olup, net marjı 7.7% dir.

Anahtar bilgiler

-13.6%

Kazanç büyüme oranı

-13.4%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.6%
Gelir büyüme oranı2.9%
Özkaynak getirisi12.0%
Net Marj7.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Gelir ve Gider Dağılımı

Sino Biopharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SEHK:1177 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2427,7902,14211,6890
31 Mar 2426,9951,99511,3780
31 Dec 2326,1991,84711,0670
30 Jun 2325,1161,25411,0010
31 Mar 2325,5711,65611,3550
31 Dec 2226,0262,05911,7090
30 Sep 2228,2415,29612,7050
30 Jun 2227,7018,04912,8460
31 Mar 2227,21513,65512,6690
31 Dec 2126,86114,60812,7040
30 Sep 2126,12912,46512,7180
30 Jun 2125,35310,01112,7540
31 Mar 2124,6683,80912,1980
31 Dec 2023,6472,77111,6290
30 Sep 2023,0392,30211,2540
30 Jun 2024,3542,55811,4900
31 Mar 2024,2482,78111,7620
31 Dec 1924,2342,76211,7970
30 Sep 1924,4799,10112,5440
30 Jun 1923,6919,12511,8010
31 Mar 1922,4449,13211,0360
31 Dec 1820,8899,04610,2680
30 Sep 1819,1032,5678,7990
30 Jun 1817,0622,4367,9210
31 Mar 1815,6092,3637,3340
31 Dec 1714,8192,1716,9050
30 Sep 1714,4912,1156,6800
30 Jun 1714,2581,8626,6680
31 Mar 1713,8991,7896,5250
31 Dec 1613,5431,6376,4930
30 Sep 1613,2711,6746,3440
30 Jun 1612,8581,6046,2720
31 Mar 1612,5071,5756,0840
31 Dec 1512,1891,4905,9740
30 Sep 1512,0301,4325,9940
30 Jun 1511,1241,4475,4830
31 Mar 1510,5521,2635,2520
31 Dec 149,9001,2104,9330
30 Sep 149,2051,0744,4570
30 Jun 148,8769514,3660
31 Mar 148,4348864,2870
31 Dec 137,7318093,9450

Kaliteli Kazançlar: 1177 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 1177 'nin mevcut net kar marjları (7.7%) geçen yılın (5%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1177 şirketinin kazançları son 5 yılda yılda 13.6% oranında azaldı.

Büyüme Hızlandırma: 1177 'un son bir yıldaki kazanç büyümesi ( 70.9% ) 5 yıllık ortalamasını (yıllık -13.6% ) aşıyor.

Kazançlar vs. Sektör: 1177 geçen yılki kazanç büyümesi ( 70.9% ) Pharmaceuticals sektörünün 9.4% değerini aştı.


Özkaynak Getirisi

Yüksek ROE: 1177 'nin Özsermaye Getirisi ( 12% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin